The Changing Cost of Cancer

Findings uncovered in “The Changing Cost of Cancer” include:

• Within the oncology space, payers most commonly manage Revlimid, Sutent, and Nexavar and have the fewest controls in place for Paclitaxel and Docetaxel
  
• Approximately 75% of payers view overall survival as the most important clinical parameter when reviewing oncology products
  
• More than 50% define "meaningful survival benefit" as 12 months or longer

Access 200 pages of valuable, credible, and actionable research that will help you make more informed and timely decisions toward the commercialization of your products. Specific data include:

• Payer and physician perspectives on the anticipated impact of biosimilars

• The potential role of comparative effectiveness

• Changes in patient cost-sharing: increased out-of-pocket requirements, trends in benefit structures, and patient assistance programs

• Off-label use: utilization patterns and recent changes to compendia

• Provider reimbursement: site of service shifts and quality initiatives in oncology

• How healthcare reform, the economy, and new trends will impact manufacturers, payers, providers, and patients
  
  Turn to Xcenda for immediate access to market data that can improve your product’s success.